Chemical regulation and kids: In search of a better fit. by Clay, R
Spheres of Influence
Regulationx
t is human nature to want to protect our children from harm.
Toys, car seats, sports equipment-all are designed with a
child's safety in mind. Those same children, however, have
been often overlooked in two critical research areas: the effects of
exposure to chemicals and guidelines for prescription medica-
tions. Environmental exposure standards have usually been set
according to research on adults, and prescription medications are
primarily designed for grown-ups as well. This has led to a short-
age of concrete information on how children's developing bodies
respond to potential hazards in their environment and to the;
drugs they may take.
"The single most important point I would liketo make is that
children are not little adults," said E. RamonaTovt ddirector of
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the Office ofChildren's Health Protection ofthe U.S. Environmental
Protection Agency (EPA), before a congressilonal subcommittee in
May. In order to learn more about children's health needs with
respect to their environments, she added, "we [the EPA] support and
encourage extensive, coordinated research to establish the scientific
basis for our risk assessments and regulatory decision making."
From the womb to the schoolyard, children may be exposed to
a wide array of environmental health contaminants, including
chemicals, lead, pesticides, fertilizers, ozone, and asbestos. Their
young metabolisms affect how they may absorb, metabolize,
,-excr,ete, and res o psychotropic drugs, anesthesia, and medica-
`!ipF9
Protctio AS such as asthma, epilepsy, severe pain, gastroin-
Fm them s, and allergic reactions. Because children are often
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overlooked in clinical trials, many are pi
scribed such drugs off-label, meaning thi
receive treatments that were not design
for that particular use or age grou
Although the practice is not illegal, litt
is known about the efficacy and safety
drugs used in this way.
"At one time, it wasn't considered eth
cal to study children in clinical tria
because children can't really give inform(
consent. They can't really understand tl
risks and benefits of participating in
trial," says Dianne Murphy, associa
director for pediatrics at the Center f
Drug Evaluation and Research ofthe U.
Food and Drug Administration (FDA).
There were also technical problems,
she says, one ofwhich was the rela-
tively large volume of blood sam-
ples frequently needed for trials,
which were difficult to obtain
from children because of the
discomfort such tests can
cause. For these and other rea-
sons, children have seldom
been enrolled in either chemi-
cal research studies or phar-
maceutical drug development
trials.
Filling the DataGap
Per pound of weight, children
drink more water, eat more food,
and breathe more air than adults,
potentially placing them at greater
risk for adverse effects from environmen-
tal exposures, says William Farland, dire
tor of the EPA National Center f,
Environmental Assessment. "We al
know that they have windows of vulner
bility," he says, meaning that there a
periods in a child's earliest development
which any damage that may occur c;
have lifelong effects.
In April 1998, Vice President Al Ge
called for the EPA "to review and repc
on what new testing may be needed
assess the special impact industrial chen
cals may have on children." In Augu
1999, the EPA announced its plans
develop a Voluntary Children's Chemic
Evaluation Program, which would evalua
chemicals with children's health concerr
Once appropriate chemicals are identifi
as having potential negative effects on ch
dren, chemical producers will be asked
voluntarily conduct any tests that mig
confirm such suspicions. The EPA is al
investigating ways to run toxicologic
studies ofthis kind.
Early on in the EPA proposal's publ
comment period, Jerome A. Paulson,
physician at the George Washingtc
University Schools ofMedicine and Pub]
re- Health, issued a response on behalf of the ago," adds
Ley Children's Environmental Health tor ofthe
ed Network (CEHN), a public interest orga- there's a re
p. nization devoted to improving children's tion about
tle health. Paulson argued that rather than what's hap
of wait until chemicals are identified for test- you could
ing-a potentially lengthy process-the articles in
ii- EPA should quickly identify and test are still ma
ils chemicals that are clearly a high priority, dering bett
ed "those in which the evidence is quite clear data about
he to in their
Ua a good han
Lte you don't k
or Concc
s. hatshindering preval
betterknowledge is t
the lack ofgooddata about
whatkids are actually
exposed to in theirlives.
It willbe veryhard to get
a goodhandle on why
theygetdiseases ifyou
don'tknow what
theyinteract with. cl
und ~c- effect c
or -Daniel Swartz Tradii
so tests done
ra- are then ex
ire that our children are highly exposed to food-use f
in them." These might be chemicals in con- developmei
an sumer products, pesticides, drinking water, tional reprn
or breast milk, or those that are inadver- evaluate po
re tently brought home by parents from their ity, extrapc
)rt place ofwork. not a perfi
to As currently written, the Voluntary Lynn Golc
ni- Children's Chemical Evaluation Program's the Depai
lst proposed test battery does not include Manageme
to acute eye and dermal irritation studies or of Hygie
cal dermal sensitization studies, according to Baltimore,
ite Paulson, because the most relevant routes natal are tl
ns. ofexposure are likely to be oral and inhala- growing an
ed tional. However, Paulson and the CEHN many chilc
til- are concerned that eliminating dermal test- cell origin.
to ing might overlook exposure from sub- periods wh
,ht stances such as soaps, shampoos, and dia- tems are ir
[so per rash creams, for example, as well as changes do
Sal from carpets, clothing, and water. A new- nent and r
born's skin, he says, is more permeable adults."
lic than that ofan older child and can absorb
,a chemicals that result in illness. Pharmace
n "On one level, we certainly have a lot Collecting
lic more information than we had 10 years the pharma
Daniel Swartz, executive direc-
CEHN. "The good news is that
,cognition that having informa-
:adults doesn't mean we know
)pening with kids. In the past,
have listed all of the relevant
a brief bibliography. But there
ljor problems today. What's hin-
:er knowledge is the lack ofgood
what kids are actually exposed
lives. It will be very hard to get
ndle on why they get diseases if
knowwhat they interact with."
ern has been growing about the
lence of pesticides and other
micals that children are exposed
o in a variety ofways, at home,
via their toys, and in the
schoolyard. Chemicals used
near schools to control
everything from bumble-
bees to mold include pes-
ticides such as organo-
phosphates, chlorpyrifos,
and synthetic
pyrethroids. Certain chil-
dren's toys are manufac-
tured with chemical plas-
ticizers called phthalates
that have been linked to
adverse health effects such
as liver and kidney damage
and testicular problems. And
many, if not most, of these
hemicals are used with little
ierstanding of their potential
Dn children's health.
tionally data have come from
on animals in which the results
ctrapolated to humans. Although
pesticide registrations require
ntal toxicity studies and genera-
oduction studies that are used to
xtential pre- and postnatal toxic-
olating from animal bioassays is
ect method. For example, says
dman, an adjunct professor in
rtment of Health Policy and
nt at the Johns Hopkins School
ne and Public Health in
,Maryland, "Prenatal and peri-
hie times when cells are rapidly
d differentiating. We know that
dhood cancers are of primitive
. If you wait to test, you miss
ere immune and metabolic sys-
mmature. Moreover, if genetic
occur, they can become perma-
*esult in increased cancer risk in
euticals
data on children has challenged
aceutical industry as well. In the
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late 1970s, the American Academy of
Pediatrics called for companies to perform
clinical trials for children so that medica-
tions would feature labels that described
dosing, usage, contraindications, and other
warnings related specifically to children.
The academy argued that it would be more
ethical to include children in clinical trials
than to continue uncontrolled experiment-
ingon them bygiving them off-label drugs.
Without proper guidelines, pediatricians
are forced to estimate dosing regimens.
"In general, two-thirds to three-quar-
ters ofthe prescriptions pediatricians write
for patients are off-label," says Murphy.
"But you can't tell them that they can't
prescribe off-label because you would cut
off care to kids who need treatment. We
don't want to deny access to children who
need these therapies."
In 1994, the FDA published a rule
requiring pharmaceutical companies to
submit any available information on their
products' potential use by children so that
the labels could be updated. The
response was disappointing, accord-
ing to Murphy. Few companies
had ever run clinical trials on r
children around the United States.
"Controlled clinical studies to evaluate the
efficacy and safety of psychotropic med-
ications for preschoolers are rare," they
report. "Because children's responses to
medications are not necessarily similar to
those of adults, systematic and careful
outcome research specifically needs to be
done for them." The report continues,
"[T]he possibility ofadverse effects on the
developing brain cannot be ruled out.
Active surveillance mechanisms for ascer-
taining subtle changes that the developing
personality may undergo as a result of a
psychotropic drug's impact on brain neu-
rotransmitters should be developed."
In March, the Clinton administration
initiated a campaign to address the issue of
the increase in the use ofsuch medications
by very young children. As part of this
Because children's
esponses to medications
children because the cost and .
n complexity ofconducting such are not necessarily sir
studies had deterred them
from making the investment. to those ofadults,
However, the last few a
years have seen new impe- systematicand care
tus for running such trials.
"Congress finally figured it outcome research specifically
out," says Murphy, "and
said, 'Look, folks, if you needs to be done forth
really want them to study
children, you'll need to offer [Tihe possibility ofadverse
an incentive.' They passed
Section III of the Food and effects on the dev
Drug Administration Modern- ization Act in 1997, which brain cannotbe ruled oL
allowed pharmaceutical companies
to obtain six more months of market
exclusivity for a product if they would
conduct pediatric drug trials. We've had a -JAMA, 23 February 2000
tremendous response to that."
One of the higher-profile medications
used off-label today is Ritalin, a stimulant effort, the FDA plans to develop new pedi
designed to treat attention disorders. atric drug labeling information for psy
Ritalin has been tested and approved for chotropic drugs used in young childrer
use in children six years old and above. and work with the National Institute c
However, in the 23 February 2000 issue Mental Health to ascertain research need
of the Journal ofthe American Medical in this area, including a proposed nation
Association, researchers from Maryland wide study ofRitalin use in children unde
and Oregon reported an acute increase in the age ofsix.
the number of preschoolers taking Ritalin Conducting clinical trials on childre
as well as antidepressants (such as Prozac), has already yielded important results. Fc
antipsychotics, and clonidine (used to example, Versed, a medication designed t
treat adult high blood pressure and insom- sedate and relax patients before operation
nia in hyperactive children). The authors was commonly used for children althoug
present data from 200,000 preschool-aged inadequate research had been done on i
nil
?ful
em,
elo,
Jt.
.1-
:0
n,
tf
is
n-
er
m
or
to
iS,
Yh
itS
ffects on them. Although Roche
'harmaceuticals (the company that manu-
Lctures Versed) had already run extensive
afety and efficacy clinical trials, the FDA
equested additional tests on special pedi-
tric populations including children with
iedical conditions that could be adversely
ffected by the medication. By observing
he responses ofpediatric patients in ahos-
ital setting before, during, and after an
peration, Roche was able to determine
hat obese children should be dosed
ccording to their ideal body weight rather
han their actual weight to avoid risk ofan
tverdose. In addition, children with con-
enital heart disease should receive a lower
iose or risk developing breathing difficul-
ies. Without this knowledge, certain chil-
lren had been placed at higher risk for
erious side effects.
iChange inThinking
'oncern over the effects ofenvironmental
nd pharmaceutical agents in children is a
worldwide issue. In an article in the 8
January 2000 issue of the British
Medical Journal, researchers
reported on the widespread use
of unlicensed and off-label
Ir drugs in pediatric wards
throughout Europe. In
response to concern about
the lack of information on
the actual effects of such
medications, the European
Union (EU) is developing
guidance on the clinical
,, * * * investigation of medicinal
products in children that
encourages pharmaceutical
companies to test new prod-
ping ucts in children when clinical-
ly appropriate.
The EU also approved an
emergency ban on certain plastic
baby toys in December 1999. The EU
feared that the phthalates used to soften
the toys could harm babies by leaching out
when infants teethe or suck on them.
It is clear that children in the United
States and abroad are increasingly finding
themselves in an environmental health
research and drug development category of
their own. Widespread pesticide use in the
schoolyard, for example, and the growing
use of psychotropic drugs in very young
populations provide just a few compelling
reasons for increasing the focus on testing
chemicals for their impact on children's
health. But the questions remain of who
should do the testing and how it should be
carried out.
RebeccaClay
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